Mesterolone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB13587 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 39 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | gout | KG + DL |
| 2 | type 1 diabetes mellitus | KG + DL |
| 3 | allergic asthma | KG + DL |
| 4 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 5 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 6 | diabetic nephropathy | KG + DL |
| 7 | intrinsic asthma | KG + DL |
| 8 | autoimmune oophoritis | KG + DL |
| 9 | Jeune syndrome situs inversus | KG + DL |
| 10 | heart disease | KG + DL |
| 11 | partial deletion of the long arm of chromosome 22 | KG + DL |
| 12 | disorder of fucoglycosan synthesis | KG + DL |
| 13 | Pierre Robin syndrome associated with a chromosomal anomaly | KG + DL |
| 14 | orofacial clefting syndrome | KG + DL |
| 15 | partial deletion of the long arm of chromosome 7 | KG + DL |
| 16 | Laubry-Pezzi syndrome | KG + DL |
| 17 | genetic syndromic Pierre Robin syndrome | KG + DL |
| 18 | interventricular septum aneurysm | KG + DL |
| 19 | pulmonary valve disease | KG + DL |
| 20 | mitral valve disease | KG + DL |
| 21 | osteoarthritis | KG + DL |
| 22 | chronic kidney disease | KG + DL |
| 23 | exostosis | KG + DL |
| 24 | bronchitis | KG + DL |
| 25 | myositis fibrosa | KG + DL |
| 26 | idiopathic granulomatous myositis | KG + DL |
| 27 | high output heart failure | KG + DL |
| 28 | tendinitis | KG + DL |
| 29 | symptomatic heart failure | KG + DL |
| 30 | diabetic ketoacidosis | KG + DL |
| 31 | pseudoachondroplasia | KG + DL |
| 32 | asthma-related traits, susceptibility to | KG + DL |
| 33 | female breast carcinoma | KG + DL |
| 34 | Lesch-Nyhan syndrome | KG + DL |
| 35 | asthma | KG + DL |
| 36 | disorder of O-xylosylglycan synthesis | KG + DL |
| 37 | osteoarthritis susceptibility | KG + DL |
| 38 | end stage renal failure | KG + DL |
| 39 | fibromyalgia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.